Publication: PLGA nanoparticles containing α-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line
Issued Date
2021-05-14
Resource Type
ISSN
10902104
0006291X
0006291X
Other identifier(s)
2-s2.0-85103100814
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biochemical and Biophysical Research Communications. Vol.553, (2021), 191-197
Suggested Citation
Theeraphong Pho-iam, Primana Punnakitikashem, Chayapol Somboonyosdech, Sirinapa Sripinitchai, Patarabutr Masaratana, Vorapan Sirivatanauksorn, Yongyut Sirivatanauksorn, Chamaiphorn Wongwan, Kytai T. Nguyen, Chatchawan Srisawat PLGA nanoparticles containing α-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line. Biochemical and Biophysical Research Communications. Vol.553, (2021), 191-197. doi:10.1016/j.bbrc.2021.03.086 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76180
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
PLGA nanoparticles containing α-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers and is a leading cause of death. Delivery of therapeutic molecules, e.g., siRNA, to HCC cells could potentially be an alternative treatment for HCC. In this study, the siRNA targeting α-fetoprotein (AFP) mRNA was found to specifically induce apoptosis and significant cell death in HepG2 cells. It also enhanced the cytotoxic effects of doxorubicin by about two-fold, making it the candidate therapeutic molecule for HCC treatment. To deliver the siRNAs into HCC cells, the AFP siRNAs were loaded into the nanoparticles based on poly (lactic-co-glycolic) acid (PLGA). These nanoparticles induced apoptosis in HepG2 cells and synergistically increased the cytotoxicity of doxorubicin. In summary, the delivery of the AFP siRNA-loaded PLGA nanoparticles in combination with doxorubicin could be a very promising approach for the treatment of HCC.